Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT
Therapeutic Advances in Respiratory Disease · 2025-10 · 19
DOI: 10.1177/17534666251384433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 09.10.2025. Verfasst von Lavinia Monaco und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality worldwide. The introduction of targeted therapies against oncogenic drivers, particularly EGFR and KRAS mutations, has significantly improved patient outcomes. However, next-generation sequencing (NGS), the current gold standard for molecular profiling, is not always accessible in routine clinical practice, emphasizing the need for noninvasive surrogate biomarkers. Radiomics has emerged as a promising imaging-based approach that extracts a large number of quantitative features from standard modalities such as [18F]FDG PET/CT. By capturing tumor heterogeneity and biological characteristics, radiomics can provide clinically relevant insights and holds potential for identifying predictive biomarkers. Recent studies suggest that CT radiomic features related to heterogeneity, texture, and shape may predict EGFR and KRAS mutation status, while the integration of metabolic parameters from [18F]FDG PET radiomics may further enhance predictive performance and offer a more comprehensive characterization of tumor biology.
Objectives
To assess the putative role of [18F]FDG PET/CT radiomic features for the prediction of mutated NSCLC. Study design: This retrospective observational study included patients with histologically confirmed NSCLC, molecularly profiled by NGS and who underwent baseline [18F]FDG PET/CT scans at Fondazione IRCCS San Gerardo dei Tintori, Monza. Tumor segmentation and radiomic feature extraction were performed on PET images using Pyradiomics, generating 766 quantitative features. Feature selection for EGFR and KRAS mutation association was conducted via repeated random subsampling and LASSO logistic regression. Data source and methods: Patients’ histological, clinical and PET/CT imaging data were obtained from the electronic clinical database and picture archiving and communication system of IRCCS Fondazione San Gerardo dei Tintori di Monza between January 2023 and December 2024. Data from 105 patients with biopsy-proven NSCLC and available NGS and [18F]FDG PET/CT scans were analyzed to identify radiomic features from PET images associated with specific mutations. Two different PET/CT scanners were used (Discovery IQ and Discovery MI, GE Healthcare), and radiomic features were extracted using IBSI-compliant algorithms, generating 766 features per tumor. Features correlated with mutations were selected using the Discovery MI dataset (55 patients) and subsequently evaluated on the independent Discovery IQ dataset (50 patients).
Results
No radiomic features were identified as associated with EGFR mutation in the Discovery MI dataset. Among the features correlated with KRAS mutation in the Discovery MI dataset, FBS_glcm_MCC—a measure of image texture complexity—was confirmed to be associated with KRAS mutation in the independent Discovery IQ dataset, with an AUC of 0.68, p = 0.04, and an odds ratio of 0.65.
Conclusion
The potential of [18F]FDG PET radiomics as a surrogate for genetic profiling in NSCLC is promising; however, these preliminary findings require further validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
- Centro di ricerca interdipartimentale Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, Università degli studi di Milano-Bicocca, Monza, Lombardy, Italy.
- Pathology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
- Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
- Tecnomed Foundation, University of Milan-Bicocca, Lombardy, Italy.
ORCID-Profile: Cinzia Crivellaro, Diego Luigi Cortinovis, Claudio Landoni, Luca Guerra
Zitieren
APA
Monaco, L., Crivellaro, C., De Bernardi, E., Bono, F., Casati, G., Seminati, D., Cortinovis, D. L., Elisei, F., L'Imperio, V., Landoni, C., Pagni, F., Turolla, E. A., Messa, C., & Guerra, L. (2025). Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251384433
Vancouver
Monaco L, Crivellaro C, De Bernardi E, Bono F, Casati G, Seminati D, et al. Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251384433
BibTeX
@article{Monaco2025,
author = {Monaco, Lavinia and Crivellaro, Cinzia and De Bernardi, Elisabetta and Bono, Francesca and Casati, Gabriele and Seminati, Davide and Cortinovis, Diego Luigi and Elisei, Federica and L'Imperio, Vincenzo and Landoni, Claudio and Pagni, Fabio and Turolla, Elia Anna and Messa, Cristina and Guerra, Luca},
title = {Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
volume = {19},
doi = {10.1177/17534666251384433}
}
EUVIMED